Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ALK status confers therapeutic sensitivity to Ensartinib in patients with Non-Small Cell Lung Cancer.
The U.S. Food and Drug Administration (FDA) granted approval to ensartinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.
This statement is based on a regulatory approval from the Food and Drug Administration:
ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.